StockData
Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc. (MCRB) stock

MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$1.41+0.00 (0.00%)

Close on Nov 17, 2026Market cap $14.02MP/E –Yield –

Seres Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Seres Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -1192.9%. For fiscal 2025 it was 721.9%, against -3509.5% the year before. The highest annual figure on record is 721.9% in fiscal 2025.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025721.9%+4231.4
FY2022Dec 31, 2022-3509.5%−3464.2
FY2021Dec 31, 2021-45.2%+223.1
FY2020Dec 31, 2020-268.3%−64.7
FY2019Dec 31, 2019-203.7%+146.3
FY2018Dec 31, 2018-350.0%−71.6
FY2017Dec 31, 2017-278.4%+142.3
FY2016Dec 31, 2016-420.7%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026622.4%+65072.4
Q1 FY2026Mar 31, 2026-5562.3%+9874.5
Q4 FY2025Dec 31, 2025-3501.1%−3537.9
Q3 FY2025Sep 30, 20252337.3%+9393.3
Q4 FY2023Dec 31, 2023-64450.0%−62707.8
Q3 FY2023Sep 30, 2023-15436.8%−10113.2
Q2 FY2023Jun 30, 202336.8%+3829.4
Q4 FY2022Dec 31, 2022-7056.0%−6363.6
Q3 FY2022Sep 30, 2022-1742.2%−1796.0
Q2 FY2022Jun 30, 2022-5323.6%−4405.3
Q1 FY2022Mar 31, 2022-3792.6%−3172.4
Q4 FY2021Dec 31, 2021-692.4%−588.5
Q3 FY2021Sep 30, 202153.8%+2190.7
Q2 FY2021Jun 30, 2021-918.3%−575.6
Q1 FY2021Mar 31, 2021-620.2%−377.5
Q4 FY2020Dec 31, 2020-103.9%+142.4
Q3 FY2020Sep 30, 2020-2136.9%−1903.5
Q2 FY2020Jun 30, 2020-342.7%−256.8
Q1 FY2020Mar 31, 2020-242.8%+89.6
Q4 FY2019Dec 31, 2019-246.4%−46.1
Q3 FY2019Sep 30, 2019-233.4%+9.0
Q2 FY2019Jun 30, 2019-85.9%+516.6
Q1 FY2019Mar 31, 2019-332.4%+370.7
Q4 FY2018Dec 31, 2018-200.3%+747.1
Q3 FY2018Sep 30, 2018-242.4%−212.3
Q2 FY2018Jun 30, 2018-602.5%+327.1
Q1 FY2018Mar 31, 2018-703.1%+141.8
Q4 FY2017Dec 31, 2017-947.4%−114.9
Q3 FY2017Sep 30, 2017-30.1%+113.5
Q2 FY2017Jun 30, 2017-929.6%–
Q1 FY2017Mar 31, 2017-844.9%–
Q4 FY2016Dec 31, 2016-832.5%–
Q3 FY2016Sep 30, 2016-143.6%–

More Seres Therapeutics figures

See a number that looks wrong?